The pharmaceutical industry still has concerns about revisions to the European Commission’s EU GMP Annex 1 for sterile drug products, which the European Medicines Agency says is a high priority item in its 2021 workplan.
Industry and regulatory experts explained some recent developments taking place with Annex 1 and addressed some areas that are still generating confusion and discussed some other “high impact” areas that will be affected by the annex at the International Society for Pharmaceutical
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?